Modality
Cell Therapy
MOA
WEE1i
Target
EZH2
Pathway
Wnt
ETMDDRB
Development Pipeline
Preclinical
~Aug 2017
→ ~Nov 2018
Phase 1
~Feb 2019
→ ~May 2020
Phase 2
~Aug 2020
→ ~Nov 2021
Phase 3
~Feb 2022
→ ~May 2023
NDA/BLA
Aug 2023
NDA/BLACurrent
NCT08596977
2,498 pts·ET
2023-08→TBD·Not yet recruiting
2,498 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-10-026mo awayEnrollment Complete· RB
Trial Timeline
Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
NDA/BLA
Not yet…
Catalysts
Enrollment Complete
2026-10-02 · 6mo away
RB
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08596977 | NDA/BLA | ET | Not yet recr... | 2498 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| Talatuximab | Samsung Biologics | Preclinical | CD3 | |
| MDG-611 | Madrigal Pharma | Approved | CGRP | |
| Cevicapivasertib | Corcept | Phase 2 | CFTR | |
| Motanaritide | Intellia | Approved | PD-1 |